13F Holdings
中文EN

LIFD LFTD PARTNERS INC.

Pharmaceutical Preparations · OTC · SEC CIK 1391135 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-15.9%
TTM net income YoY-53,461.9%
TTM EPS YoY—
Revenue 3-yr CAGR-14.3%
Net income 3-yr CAGR—

Margins

Gross margin8.3%
Operating margin-27.9%
Net margin-108.9%
FCF margin2.1%
EBITDA margin-26.8%

Returns

ROE-164.2%
ROA-127.1%
ROIC (approx.)-38.3%
Asset turnover1.17x

Leverage & solvency

Liabilities / assets55.7%
Debt / equity0.00x
Current ratio1.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-130.2%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$36.92M$37.33M$51.61M$57.42M$31.66M
Cost of revenue$24.30M$24.57M$31.91M$36.42M$15.72M
Gross profit$12.62M$12.75M$19.70M$20.99M$15.94M
R&D expense——$19,800$19,800—
Operating income$913,208-$773,464$2.41M$9.81M$7.78M
Interest expense——$110,517$120,197$142,427
Pretax income-$24.43M-$2.38M$2.76M$9.99M$7.17M
Income tax$432,824-$524,425$598,065-$2.80M$1.37M
Net income-$24.86M-$1.86M$2.16M$7.20M$5.80M
EBITDA$1.47M-$252,833$2.84M$10.00M$7.87M
EPS (basic)-1.68-0.130.150.510.50
EPS (diluted)-1.68-0.130.130.450.43
Weighted avg. shares (diluted)14.82M14.80M16.44M15.86M13.36M
Banking
Deposits$1.00M$1.00M———
Balance sheet
Cash & equivalents$1.77M$3.15M$5.36M$3.53M$1.60M
Receivables$2.53M$2.66M$3.59M$2.41M$3.46M
Inventory$10.96M$9.32M$10.17M$6.02M$3.81M
Current assets$15.69M$17.23M$21.67M$13.85M$13.15M
PP&E, net$2.27M$2.70M$3.00M$1.02M$433,213
Goodwill$0$23.09M$23.09M$22.29M$22.29M
Intangibles$0——$0$1,386
Total assets$19.27M$47.62M$51.35M$41.13M$39.42M
Current liabilities$5.16M$6.39M$8.69M$6.21M$11.91M
Total liabilities$6.64M$10.12M$12.53M$6.59M$11.96M
Shareholders' equity$12.63M$37.50M$38.82M$34.54M$27.46M
Shares outstanding14.82M14.82M14.81M14.10M14.03M
Cash flow statement
Operating cash flow$1.32M-$960,067$638,925$3.04M$5.62M
Capital expenditure$121,639$313,763$789,662$916,119$368,223
Free cash flow$1.20M-$1.27M-$150,737$2.12M$5.25M
Investing cash flow-$121,639-$479,574-$2.52M-$916,119-$446,655
Financing cash flow-$2.58M-$770,951$3.70M-$193,416-$4.01M
Depreciation & amortization$552,877$520,631$425,614$191,541$90,146
Stock-based compensation———$0$0
Dividends paid————$11,844
Share buybacks$0$240,240$0$150,000$34,200

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.